Anthera Pharmaceuticals

Anthera screens first patient in pivotal Sollpura study

Wednesday, May 17, 2017

Anthera Pharmaceuticals has commenced screening in the RESULT phase III clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis. Based on feedback from the FDA, this non-inferiority study will compare the efficacy of Sollpura, a biologically manufactured pancreatic enzyme replacement therapy (PERT), to Pancreaze, a porcine-extracted PERT, as assessed by CFA after four weeks of treatment. Topline data are expected at the end of 2017 or early 2018, depending on the speed of patient enrollment.

[Read More]

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

[Read More]